Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Roots Analysis | PRODUCT CODE: 1086401

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1086401

DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Synthesis and Enzymatic Synthesis), Key Applications Areas (Research and Diagnostics and Therapeutic Applications),

PUBLISHED:
PAGES: 199 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Title:
DNA Synthesis Technologies and Services
Market, Distribution by Method of DNA Synthesis (Chemical Synthesis and Enzymatic Synthesis), Key Applications Areas (Research and Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Overview

DNA or RNA molecules find a variety of applications in the biopharmaceutical industry for genetic testing, medical research, therapeutic development, forensic investigation, and other analytical processes. It is worth highlighting that several research studies are being conducted to evaluate the use of oligonucleotides, especially DNA, as a therapeutic intervention for treatment of various medical conditions. The approval of the first antisense oligonucleotide drug, Fomivirse, in 1998, led to a surge in the demand of DNA-based interventions. In addition to the application of DNA in therapy development, these entities are also being deployed in genetic diagnostics and have already proven their use in identifying patients across a diverse range of diseases including breast cancer, dyslexia, ovarian cancer, Parkinson's disease and psoriasis. The advances in medical research have led to establishment of several technologies that can sequence, analyze, and edit different forms of DNA. This, coupled to the increasing use of DNA across diverse range of applications, have urged industry experts to actively look for efficient DNA synthesis technologies that not only facilitate parallelized synthesis of DNA but also provide unmatched precision, scalability, and speed.

It is worth noting that several companies have developed proprietary enzymatic DNA synthesis platforms offering distinct advantages (such as the potential to increase length of DNA fragment, greater accessibility and convenience) over conventional DNA synthesis methods. Given the known merits of such technologies, a significant proportion of medical researchers and therapy / diagnostic developers prefer to outsource DNA synthesis operations to third party platforms / service providers who claim to provide the expertise in DNA synthesis and production. Presently, there are over 65 players that offer DNA synthesis technologies / services, and these players are actively undertaking efforts to build / expand their existing capabilities, in order to cater to the growing demand for DNA synthesis. Given the rising need for DNA across a wide range of applications, we are led to believe that the DNA synthesis platforms and services industry is likely to witness noteworthy growth in the foreseen future.

Scope of the Report

The "DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Method and Enzymatic Method), Key Applications Areas (Research & Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global, 2022-2035" report features report features a detailed study of the current scenario and future potential of the DNA synthesis technologies and service providers. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, the study covers:

  • A detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.
  • Elaborate profiles of the key players involved in providing technologies and services in the DNA synthesis domain. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information, and recent developments and an informed future outlook.
  • A detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
  • A detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
  • An analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals.
  • A review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • An in-depth analysis of grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, in the period between 2017 and 2022, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers.
  • A detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).
  • An in-depth analysis of the patents related to DNA synthesis technologies, filed / granted till 2022, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

One of the key objectives of the report was to estimate the existing market size and the future growth opportunities in DNA synthesis technologies and services market, over the next decade. Based on multiple parameters, such as number of projects and service-based cost distribution we have developed informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across methods of DNA synthesis (chemical method and enzymatic method), application areas (research & diagnostics and therapeutic applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry's growth.

The report also features detailed transcripts of interview(s) held with representatives of renowned organizations that are engaged in the DNA synthesis technologies and services industry.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players offering DNA synthesis technologies and services?
  • What are the recent developments and emerging trends in the DNA synthesis technologies and services domain?
  • Which partnership models are commonly adopted by industry stakeholders in the DNA synthesis technologies and services industry?
  • Which are the leading funding organizations providing grants in the DNA synthesis industry?
  • What is the trend of capital investments in the DNA synthesis technologies and services market?
  • What is the focus of various publications related to DNA synthesis technologies and services?
  • How has the intellectual property landscape for DNA synthesis technologies and services market evolved over the years?
  • Which factors are likely to influence the evolution of the upcoming DNA synthesis technologies and services market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the DNA synthesis technologies and services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to DNA synthesis technologies. The chapter features a detailed discussion on the components of DNA synthesis, leading and lagging strand synthesis and the chemical and enzymatic method of DNA synthesis. In addition, it discusses the various applications and future prospects of display technologies.

Chapter 4 provides a detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.

Chapter 5 features elaborate profiles of the key players involved in providing technologies and services for DNA synthesis. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information and recent developments and an informed future outlook.

Chapter 6 is a case study featuring a detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 7 is a case study featuring a detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 8 features an analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals.

Chapter 9 features a review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such year of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 10 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, during the period, 2017- 2022, on the basis of important parameters, such as year of grant award, amount awarded, type of funding institute, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization, study section and type of grant application. The chapter also highlights the popular recipient organizations (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 11 provides a detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 12 provides an overview of the various patents that have been filed / granted, since 2017, based on various parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 13 includes an insightful market forecast analysis, highlighting growth opportunities of DNA synthesis services market till the year 2035. In addition, we have provided inputs on the likely distribution of the market opportunity based on different method of DNA synthesis (chemical method and enzymatic method), application area (research & diagnostics, and therapeutics applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the DNA synthesis services and technologies market.

Chapter 15 is a collection of interview transcript(s) of the discussions held with key stakeholders in this industry.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to DNA Synthesis
  • 3.3. Components of DNA Synthesis
    • 3.3.1. Substrates
    • 3.3.2. Template
    • 3.3.3. Primer
    • 3.3.4. Enzymes
    • 3.3.5. Leading Strand Synthesis
    • 3.3.6. Lagging Strand Synthesis
  • 3.4. DNA Synthesis Technologies
    • 3.4.1. Chemical Method of DNA Synthesis
    • 3.4.2. Enzymatic Method of DNA Synthesis
  • 3.5. Applications of DNA Synthesis
  • 3.6. Future Perspectives

4. MARKET OVERVIEW: DNA SYNTHESIS TECHNOLOGIES AND SERVICES

  • 4.1. Chapter Overview
  • 4.2. DNA Synthesis Technologies and Services: Overall Market Landscape
    • 4.2.1. Analysis by Type of Offering
    • 4.2.2. Analysis by Method of DNA Synthesis
    • 4.2.3. Analysis by Type of DNA Molecule
    • 4.2.4. Analysis by Custom Offerings
    • 4.2.5. Analysis by Application Area
  • 4.3. DNA Synthesis Technologies and Services: Key Industry Players
    • 4.3.1 Analysis by Year of Establishment
    • 4.3.2 Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Application Area and Region

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Ajinomoto Bio-Pharma Services
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Technology / Service Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. ATUM
    • 5.3.1. Company overview
    • 5.3.2. Technology / Service Portfolio
    • 5.3.3. Recent Developments and Future Outlook
  • 5.4. DNA Script
    • 5.4.1. Company Overview
    • 5.4.2. Technology / Service Portfolio
    • 5.4.3. Recent Developments and Future Outlook
  • 5.5. Eurofins Genomics
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Technology / Service Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Gene Universal
    • 5.6.1. Company Overview
    • 5.6.2. Technology / Service Portfolio
    • 5.6.3. Recent Developments and Future Outlook
  • 5.7. GenScript
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Technology / Service Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Synbio Technologies
    • 5.8.1. Company overview
    • 5.8.2. Technology / Service Portfolio
    • 5.8.3. Recent Developments and Future Outlook

6. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

  • 6.1. Chapter Overview
  • 6.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Scale of Operation
    • 6.2.4. Analysis by Geographical Location
    • 6.2.5. Analysis by Location of Manufacturing Facilities
    • 6.2.6. Analysis by Regulatory Accreditations / Certifications Received
    • 6.2.7. Analysis by Type of Oligonucleotide Manufactured
    • 6.2.8. Analysis by Type of Offering
    • 6.2.9. Analysis by Type of Manufacturing Service Offered
    • 6.2.10. Analysis by Type of Modification

7. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)

  • 7.1. Chapter Overview
  • 7.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Scale of Operation
    • 7.2.4. Analysis by Geographical Location
    • 7.2.5. Analysis by Location of Manufacturing Facilities
    • 7.2.6. Analysis by Regulatory Accreditations / Certifications
    • 7.2.7. Analysis by Type of Oligonucleotide Manufactured
    • 7.2.8. Analysis by Type of Offering
    • 7.2.9. Analysis by Type of Manufacturing Service Offered
    • 7.2.10. Analysis by Type of Modification

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. DNA Synthesis Technologies and Services: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Partner
    • 8.3.4. Analysis by Year and Type of Partner
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships
    • 8.3.6. Regional Analysis
      • 8.3.6.1. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. DNA Synthesis Technologies: Recent Funding Instances
  • 9.4. Analysis by Year of Investment
  • 9.5. Analysis by Amount Invested
  • 9.5. Analysis by Amount Invested
  • 9.6. Analysis by Type of Funding and Amount Invested
  • 9.7. Analysis by Venture Capital Funding
  • 9.8. Most Active Players: Analysis by Number of Funding Instances
  • 9.9. Key Investors: Analysis by Number of Funding Instances
  • 9.10. Regional Analysis by Amount Invested
  • 9.11. Funding and Investment Summary

10. GRANT ANALYSIS

  • 10.1 Chapter Overview
  • 10.2. Analysis Methodology and Key Parameters
  • 10.3. DNA Synthesis Technologies and Services: List of Academic Grants
    • 10.3.1. Analysis by Year of Grant Award
    • 10.3.2. Analysis by Grant Amount Awarded
    • 10.3.3. Analysis by Administering Institute Center
    • 10.3.4. Analysis by Support Period
    • 10.3.5. Analysis by Administering Institute Center and Support Period
    • 10.3.6. Analysis by Type of Grant Application
    • 10.3.7. Analysis by Grant Activity Code
    • 10.3.8. Word Cloud of Study Titles
    • 10.3.9. Analysis by Purpose of Grant Award
    • 10.3.10. Popular NIH Departments: Analysis by Number of Grants
    • 10.3.11. Analysis by Type of Recipient Organization
  • 10..12. Prominent Program Officers: Analysis by Number of Grants

11. PUBLICATION ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Analysis Methodology and Key Parameters
  • 11.3. Analysis by Year of Publication
  • 11.4. Analysis by Quarterly Distribution of Publication
  • 11.5. Analysis by Type of Article
  • 11.6. Analysis by Popular Keywords
  • 11.7. Most Popular Authors: Analysis by Number of Publications
  • 11.8. Popular Publishers: Analysis by Number of Publications
  • 11.9. Popular Journals: Analysis by Number of Publications
  • 11.10. Analysis by Therapeutic Area
  • 11.11. Geographical Analysis

12. PATENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Analysis Methodology and Key Parameters
  • 12.3. DNA Synthesis Technologies and Services: Patent Analysis
    • 12.3.1. Analysis by Type of Patent
    • 12.3.2. Analysis by Publication Year
    • 12.3.3. Analysis by Type of Patent and Publication Year
    • 12.3.3. Analysis by Issuing Authority
    • 12.3.4. Analysis by CPC Symbols
    • 12.3.5. Analysis by Type of Applicant
    • 12.3.6. Word Cloud Analysis: Emerging Focus Areas
    • 12.3.7. Leading Industry Players: Analysis by Number of Patents
    • 12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 12.3.9. Leading Players: Analysis by Number of Patents
    • 12.3.10. Leading Patents: International Patents
    • 12.3.11. Analysis by Patent Characteristics
    • 12.3.12. Patent Valuation Analysis

13. DNA SYNTHESIS SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1 Chapter Overview
  • 13.2. Key Assumptions and Forecast Methodology
  • 13.3. Global DNA Synthesis Services Market, 2022-2035
    • 13.3.1. Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035
    • 13.3.2. Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035
    • 13.3.3. Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035
    • 13.3.4. Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035
  • 13.4. DNA Synthesis Services Market in North America, 2022-2035
    • 13.4.1. DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035
    • 13.4.2. DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035
    • 13.4.3. DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035
  • 13.5. DNA Synthesis Services Market in Europe, 2022-2035
    • 13.5.1. DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035
    • 13.5.2. DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035
    • 13.5.3. DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035
  • 13.6. DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022-2035
    • 13.6.1. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035
    • 13.6.2. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035
    • 13.6.3. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035

14. CONCLUDING REMARKS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 DNA Synthesis 5' to 3'
  • Figure 3.2 DNA Synthesis: Direction of Fork Movement
  • Figure 3.3 Leading Strand Synthesis
  • Figure 3.4 Lagging Strand Synthesis
  • Figure 3.5 Applications of DNA Synthesis
  • Figure 4.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
  • Figure 4.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
  • Figure 4.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
  • Figure 4.4 DNA Synthesis Technologies and Services: Distribution by Custom Offerings
  • Figure 4.5 DNA Synthesis Technologies and Services: Distribution by Application Area
  • Figure 4.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
  • Figure 4.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
  • Figure 4.8 DNA Synthesis Technologies and Service Providers: Distribution by Location of Headquarters
  • Figure 4.9 DNA Synthesis Technologies and Service Providers: Distribution by Application Area and Region
  • Figure 5.1 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
  • Figure 5.2 Eurofins Genomics: Annual Revenues FY 2018- FY 2021 (JPY Billion)
  • Figure 5.3 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
  • Figure 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Figure 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Figure 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Figure 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Geographical Location
  • Figure 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 6.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
  • Figure 6.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Figure 6.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
  • Figure 6.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
  • Figure 6.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
  • Figure 6.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Figure 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Figure 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Figure 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Figure 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Geographical Location
  • Figure 7.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 7.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
  • Figure 7.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Figure 7.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
  • Figure 7.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering
  • Figure 7.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
  • Figure 7.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
  • Figure 8.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.7 Partnerships and Collaborations: Regional Distribution
  • Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 DNA Synthesis Technologies: Cumulative Distribution by Year of Investment, 2017-2022
  • Figure 9.2 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017- 2022 (USD Million)
  • Figure 9.3 Funding and Investments: Distribution by Type of Funding
  • Figure 9.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 9.5 Funding and Investments: Distribution by Type of Venture Capital Funding
  • Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.7 Most Active Players: Distribution by Amount Raised, 2017-2022 (USD Million)
  • Figure 9.8 Funding and Investments: Distribution of Investors by Number of Instances
  • Figure 9.9 Funding and Investments: Regional Distribution by Amount Invested, 2017-2022
  • Figure 9.10 Summary of Funding and Investments
  • Figure 10.1. Grant Analysis: Distribution by Year of Grant Award (FY 2017 - Q1 2022)
  • Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded (USD Million)
  • Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
  • Figure 10.4. Grant Analysis: Distribution by Support Period
  • Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
  • Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
  • Figure 10.8. Word Cloud Analysis: Emerging Focus Areas
  • Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 10.10. Popular NIH Departments: Distribution by Number of Grants
  • Figure 10.11. Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
  • Figure 11.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
  • Figure 11.2 Publication Analysis: Quarterly Distribution of Publications, 2017-2022
  • Figure 11.3 Publication Analysis: Distribution by Type of Article
  • Figure 11.4 Word Cloud Analysis: Emerging Focus Areas
  • Figure 11.5 Analysis by Popular Keywords
  • Figure 11.6 Most Popular Authors: Distribution by Number of Publications
  • Figure 11.7 Popular Publishers: Distribution by Number of Publications
  • Figure 11.8 Popular Journals: Distribution by Number of Publications
  • Figure 11.9 Publication Analysis: Distribution by Therapeutic Area
  • Figure 11.10 Publication Analysis: Distribution by Geography
  • Figure 12.1 Patent Analysis: Distribution by Type of Patent
  • Figure 12.2 Patent Analysis: Cumulative Distribution by Publication Year (Pre-2017, Q1 2022)
  • Figure 12.3 Patent Analysis: Year-wise Distribution of Granted Patents, Pre-2017, Q1 2022
  • Figure 12.4 Patent Analysis: Year-wise Distribution of Filed Patents, Pre-2017, Q1 2022
  • Figure 12.5 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Figure 12.6 Patent Analysis: Distribution by Issuing Authority
  • Figure 12.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 12.9 Word Cloud Analysis: Emerging Focus Areas
  • Figure 12.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 12.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 12.12 Patent Analysis: Distribution by Patent Age
  • Figure 12.13 Patent Analysis: Distribution by Relative Valuation
  • Figure 13.1 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Figure 13.2 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
  • Figure 13.3 Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035 (USD Million)
  • Figure 13.4 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
  • Figure 13.5 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
  • Figure 13.6 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Figure 13.7 DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035 (USD Million)
  • Figure 13.8 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
  • Figure 13.9 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
  • Figure 13.10 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Figure 13.11 DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035 (USD Million)
  • Figure 13.12 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
  • Figure 13.13 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
  • Figure 13.14 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Figure 13.15 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035 (USD Million)
  • Figure 13.16 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)
  • Figure 14.1 Concluding Remarks: Overall Market Landscape of DNA Synthesis Technologies and Services
  • Figure 14.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 14.3 Concluding Remarks: Funding and Investments
  • Figure 14.4 Concluding Remarks: Grant Analysis
  • Figure 14.5 Concluding Remarks: Publication Analysis
  • Figure 14.6 Concluding Remarks: Patent Analysis

List Of Tables

  • Table 4.1 DNA Synthesis Technologies and Services: Information on Developers, Type of Offering, Method of DNA Synthesis, Type of DNA Molecule, Custom Offerings and Type of Application Area
  • Table 4.2 DNA Synthesis Technologies and Services Providers: Information on Year of Establishment, Company Size and Geography
  • Table 5.1 DNA Synthesis Technology and Service Providers: List of Companies Profiled
  • Table 5.2 Ajinomoto Bio-Pharma Services: Company Snapshot
  • Table 5.3 Ajinomoto Bio-Pharma Services: Technology / Service Portfolio
  • Table 5.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 5.5 ATUM: Company Snapshot
  • Table 5.6 ATUM: Technology / Service Portfolio
  • Table 5.7 DNA Script: Company Snapshot
  • Table 5.8 DNA Script: Technology / Service Portfolio
  • Table 5.9 DNA Script: Recent Developments and Future Outlook
  • Table 5.10 Eurofins Genomics: Company Snapshot
  • Table 5.11 Eurofins Genomics: Technology / Service Portfolio
  • Table 5.12 Gene Universal: Company Snapshot
  • Table 5.13 Gene Universal: Technology / Service Portfolio
  • Table 5.14 GenScript: Company Snapshot
  • Table 5.15 GenScript Technology / Service Portfolio
  • Table 5.16 GenScript: Recent Developments and Future Outlook
  • Table 5.17 Synbio Technologies: Company Snapshot
  • Table 5.18 Synbio Technologies: Technology / Service Portfolio
  • Table 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
  • Table 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
  • Table 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Service(s) Offered
  • Table 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
  • Table 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
  • Table 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
  • Table 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
  • Table 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
  • Table 7.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
  • Table 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
  • Table 8.1 DNA Synthesis Technologies and Services Providers: List of Partnerships and Collaborations, 2017-2022 (till March)
  • Table 9.1 DNA Synthesis Technologies: List of Funding Instances, 2017-2022 (till March)
  • Table 9.2 Funding and Investment Analysis: Summary of Investments
  • Table 10.1 DNA Synthesis Technologies and Services: List of Academic Grants
  • Table 12.1 Patent Analysis: CPC Symbols
  • Table 12.2 Patent Analysis: Most Popular CPC Symbols
  • Table 12.3 Patent Analysis: List of Top 10 CPC Symbols
  • Table 12.4 Patent Analysis: List of Relatively High Value Patents
  • Table 16.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
  • Table 16.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
  • Table 16.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
  • Table 16.4 DNA Synthesis Technologies and Services: Distribution by Custom Synthesis
  • Table 16.5 DNA Synthesis Technologies and Services: Distribution by Application Area
  • Table 16.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
  • Table 16.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
  • Table 16.8 DNA Synthesis Technologies and Service Providers Distribution by Location of Headquarters
  • Table 16.9 DNA Synthesis Technologies and Service Providers Distribution by Application and Region
  • Table 16.10 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
  • Table 16.11 Eurofins Genomics: Annual Revenues FY 2018- H1 2021 (JPY Billion)
  • Table 16.12 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
  • Table 16.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Table 16.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Table 16.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Table 16.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
  • Table 16.17 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 16.18 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
  • Table 16.19 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Table 16.20 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
  • Table 16.21 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
  • Table 16.22 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
  • Table 16.23 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Table 16.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Table 16.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Table 16.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Table 16.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters6
  • Table 16.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 16.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
  • Table 16.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Table 16.31 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
  • Table 16.32 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering16
  • Table 16.33 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
  • Table 16.34 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
  • Table 16.35 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
  • Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.37 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
  • Table 16.38 Most Active Players: Distribution by Number of Partnerships
  • Table 16.39 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 16.40 Partnerships and Collaborations: Distribution by Year and Type of Partner
  • Table 16.41 Partnerships and Collaborations: Regional Distribution
  • Table 16.42 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 16.43 DNA Synthesis Technologies: Distribution by Year of Investment, 2017-2022
  • Table 16.44 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017-2022 (USD Million)
  • Table 16.45 Funding and Investments: Distribution by Type of Funding
  • Table 16.46 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 16.47 Distribution by Type of Venture Capital Funding
  • Table 16.48 Most Active Players: Distribution by Number of Funding Rounds
  • Table 16.49 Most Active Players: Distribution by Amount Raised 2017-2022 (USD Million)
  • Table 16.50 Funding and Investment: Distribution of investors by number of instances
  • Table 16.51 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, 2017-2022
  • Table 16.52 Grant Analysis: Distribution by Year of Grant Award
  • Table 16.53 Grant Analysis: Distribution by Grant Amount Awarded
  • Table 16.54 Grant Analysis: Distribution by Administering Institute Center
  • Table 16.55 Grant Analysis: Distribution by Support Period
  • Table 16.56 Grant Analysis: Distribution by Administering Institute Center and Support Year
  • Table 16.57 Grant Analysis: Distribution by Type of Grant Application
  • Table 16.58 Grant Analysis: Distribution by Grant Activity Code
  • Table 16.59 Grant Analysis: Word Cloud of Study Titles
  • Table 16.60 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 16.61 Grant Analysis: Distribution by Type of Recipient Organization
  • Table 16.62 Popular NIH Departments: Distribution by Number of Grants
  • Table 16.63 Prominent Program Officers: Distribution by Number of Grants
  • Table 16.64 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
  • Table 16.65 Publication Analysis: Quarterly Distribution of Publications
  • Table 16.66 Publication Analysis: Distribution by Type of Article
  • Table 16.67 Publication Analysis: Word Cloud of Study Titles
  • Table 16.68 Analysis by Popular Keywords
  • Table 16.69 Most Popular Authors: Distribution by Number of Publications
  • Table 16.70 Popular Publishers: Distribution by Number of Publications
  • Table 16.71 Popular Journals: Distribution by Number of Publications
  • Table 16.72 Popular Journals: Distribution by Number of Publications
  • Table 16.73 Publication Analysis: Distribution by Geography
  • Table 16.74 Patent Analysis: Distribution by Type of Patent
  • Table 16.75 Patent Analysis: Cumulative Distribution by Publication Year
  • Table 16.76 Patent Analysis: Distribution of Granted Patents by Publication Year
  • Table 16.77 Patent Analysis: Distribution of Filed Patents Publication Year
  • Table 16.78 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Table 16.79 Patent Analysis: Distribution by Issuing Authority
  • Table 16.80 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 16.81 Leading Industry Players: Distribution by Number of Patents
  • Table 16.82 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 16.83 Patent Analysis: Distribution by Patent Age
  • Table 16.84 Patent Analysis: Distribution by Relative Valuation
  • Table 16.85 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Table 16.86 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
  • Table 16.87 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
  • Table 16.88 Global DNA Synthesis Services Market: Distribution by Type of Application Area, 2022-2035 (USD Million)
  • Table 16.89 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
  • Table 16.90 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
  • Table 16.91 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Table 16.92 DNA Synthesis Services Market in North America: Distribution by Type of Application Area , 2022-2035 (USD Million)
  • Table 16.93 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
  • Table 16.94 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
  • Table 16.95 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Table 16.96 DNA Synthesis Services Market in Europe: Distribution by Type of Application Area, 2022-2035 (USD Million)
  • Table 16.97 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
  • Table 16.98 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
  • Table 16.99 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
  • Table 16.100 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Application Area, 2022-2035 (USD Million)
  • Table 16.101 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  • 1. Ajinomoto Bio-Pharma Services
  • 2. Aldevron
  • 3. AltaBioscience
  • 4. Ansa Biotechnologies
  • 5. Arbor Biosciences
  • 6. ATUM
  • 7. Beijing SBS
  • 8. Bio Basic
  • 9. Biolegio
  • 10. Biomatik
  • 11. Bioneer
  • 12. Biosearch Technologies
  • 13. Bio-Synthesis
  • 14. Blue Heron Biotech
  • 15. BOC Sciences
  • 16. BR Biochem Life Sciences
  • 17. Camena Bioscience
  • 18. Catalog
  • 19. ChemGenes Corporation
  • 20. Creative Biogene
  • 21. CustomArray
  • 22. CyberGene
  • 23. Dalton Pharma Services
  • 24. DNA Script
  • 25. Eton Bioscience (Subsidiary of Codex DNA)
  • 26. Eurofins Genomics
  • 27. Eurogentec
  • 28. Evonetix
  • 29. Futuresynthesis
  • 30. Gene Universal
  • 31. General Biosystems
  • 32. Generi Biotech
  • 33. Genewiz
  • 34. GenScript
  • 35. Glen Research
  • 36. Helixworks Technologies
  • 37. IBA Lifesciences
  • 38. Integrated DNA Technologies
  • 39. Iridia
  • 40. KareBay Biochem
  • 41. Kern Systems
  • 42. Kilobaser
  • 43. LC Sciences
  • 44. metabion
  • 45. Microsoft
  • 46. Microsynth
  • 47. Midland Certified Reagent Company
  • 48. Molecular Assemblies
  • 49. Moligo Technologies
  • 50. Nitto Denko Avecia
  • 51. Nuclera Nucleics
  • 52. Oligomer Biotechnology
  • 53. Origene
  • 54. ProMab Biotechnologies
  • 55. ProteoGenix
  • 56. Quintaribio
  • 57. Ribbon Biolabs
  • 58. SARTOMED
  • 59. Sigma-Aldrich (Acquired by Merck)
  • 60. Sunomix Biosciences
  • 61. Synbio Technologies
  • 62. Syngene
  • 63. SynHelix
  • 64. Synthomics
  • 65. TAG Copenhagen
  • 66. Thermo Fisher Scientific
  • 67. Xcelris Labs
  • 68. Yale School of Medicine
  • 69. GE Research
  • 70. Baseclick
  • 71. French Ministry for Armed Forces
  • 72. Dynamic Combinatorial Chemistry (DCC)
  • 73. Bright Peak Therapeutics
  • 74. Trio Pharmaceuticals
  • 75. GeneDesign
  • 76. BIOfidal
  • 77. Transcenta
  • 78. Amptec
  • 79. Eton Bioscience
  • 80. Glen Research Corporation
  • 81. CodexisCodexis
  • 82. TeselaGen Biotechnology
  • 83. Analog Devices
  • 84. imec
  • 85. LioniX International
  • 86. PeproTech
  • 87. Patheon
  • 88. GSL Biotech
  • 89. Twist Bioscience
  • 90. Horizon Discovery
  • 91. CustomArray
  • 92. Blue Heron Biotech
  • 93. SynHelix
  • 94. Isolere Bio
  • 95. Aldevron
  • 96. Biotechnolabs
  • 97. iGEM
  • 98. Integrated DNA Technologies
  • 99. GENEWIZ
  • 100. Eurofins Genomics
  • 101. Kazusa DNA Research Institute
  • 102. GeneBay
  • 103. Aldevron
  • 104. Agilent Technologies
  • 105. Illumina Ventures
  • 106. Sofinnova Partners
  • 107. Kurma Partners
  • 108. Casdin Capital
  • 109. Danaher Life Sciences
  • 110. M Ventures
  • 111. Columbia Threadneedle Investments
  • 112. Casdin Capital
  • 113. Alexandria Venture Investments
  • 114. iSelect Fund
  • 115. Codexis
  • 116. Argonautic Ventures
  • 117. Horizons Ventures
  • 118. Mubadala Capital
  • 119. Humboldt Fund
  • 120. National Science Foundation
  • 121. Civilization Ventures
  • 122. Illumina Ventures
  • 123. Merck Ventures
  • 124. Idinvest Partners
  • 125. Bpifrance
  • 126. Bpifrance
  • 127. Life Sciences Partners
  • 128. M. Ventures
  • 129. Kurma Partners and Idinvest Partners
  • 130. Bpifrance
  • 131. Merck
  • 132. Life Sciences Partners
  • 133. Bpifrance
  • 134. Life Science Partners
  • 135. Bpifrance Large Venture Fund
  • 136. Alexandria Venture
  • 137. Fidelity Management and Research
  • 138. Arrowmark Partners
  • 139. Farallon Capital
  • 140. Moore Strategic Ventures
  • 141. National Human Genome Research Institute
  • 142. Coatue Management
  • 143. Catalio Capital Management
  • 144. Fidelity Management & Research Company
  • 145. eureKARE
  • 146. Irving Investors
  • 147. IST Cube
  • 148. tecnet equity
  • 149. Hadean Ventures
  • 150. Lansdowne Partners
  • 151. Helicase Venture
  • 152. IST cube
  • 153. tecnet equity
  • 154. iSelect Fund
  • 155. Keshif Ventures
  • 156. Agilent Technologies
  • 157. LYFE Capital
  • 158. National Human Genome Research Institute
  • 159. SynBio Innovation Accelerator
  • 160. LYFE Capital
  • 161. DCVC
  • 162. Rising Tide
  • 163. Providence Investment Company Limited
  • 164. Molten Ventures
  • 165. Cambridge Consultants
  • 166. Innovate UK
  • 167. Draper Esprit
  • 168. The Morningside Group
  • 169. Providence Investment Company
  • 170. Cambridge Consultants
  • 171. Rising Tide Fund
  • 172. Tech Coast Angels
  • 173. The Department of Air Force
  • 174. Department of Health and Human Services
  • 175. TEEC Angel Fund
  • 176. TA Associates
  • 177. Colibri Ventures
  • 178. Vanderbilt University
  • 179. Division of Basic Sciences
  • 180. Columbia University Health Sciences
  • 181. Medical College of Wisconsin
  • 182. Eunice Kennedy Shriver National Institute of Child Health & Human Development
  • 183. Univ Of North Carolina Chapel Hill
  • 184. Weill Medical Coll of Cornell Univ
  • 185. University of Minnesota
  • 186. University of Iowa
  • 187. National Institute on Aging
  • 188. National Institute of Environmental Health Sciences
  • 189. University of Wisconsin-Madison
  • 190. Life Technologies
  • 191. Tosoh
  • 192. Achillion Pharmaceuticals
  • 193. Harvard College
  • 194. Broad Inst
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!